# Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

> **NCT06916975** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jin Xu** · enrollment: 46 (estimated)

## Conditions studied

- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** AG

## Key facts

- **NCT ID:** NCT06916975
- **Lead sponsor:** Jin Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916975, "Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT06916975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*